Septerna盘前涨超65% 与诺和诺德合作开发针对肥胖及其他心代谢疾病的口服小分子药物

金吾资讯
14 May

金吾财讯 | Septerna(SEPN)盘前股价暴力拉升,暂涨65.92%,报11.16美元。消息面上,公司与诺和诺德达成合作与许可协议,共同开发用于治疗肥胖症、2型糖尿病和其他心脏代谢疾病的口服小分子药物。诺和诺德是广受欢迎的减肥药Wegovy的制造商,该公司试图通过开发下一代药物、收购和合作来进一步巩固其在潜在的1500亿美元肥胖症市场中的地位。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10